|Description||Efegatran is a thrombin inhibitor under the development of Eli Lilly. It can be used for the treatment of thromboembolic disorders. No development reported was reported for the treatment of Thrombosis.|
|Synonyms||Efegatran;RGH2958; LY 294468; (S)-1-(D-phenylalanyl)-N-((S)-5-guanidino-1-oxopentan-2-yl)pyrrolidine-2-carboxamide sulfate|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Eli Lilly|
Eltrombopag is a is an agonist of the c-mpl (TpoR) receptor used as treatment for thrombocytopenia.It has been developed for certain conditions that lead to thr...
Dabigatran ethyl ester
Dabigatran ethyl ester is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. Dabigatran provides a stable anticoagulation effect w...
Dabigatran etexilate mesylate
Dabigatran etexilate mesylate is the orally active prodrug of dabigatran. It is a reversible and selective, direct thrombin inhibitor (DTI).
SFLLRNPNDKYEPF is a synthetic thrombin receptor agonist peptide and causes platelet aggregation (EC50 = 4 μM) and secretion .
Bivalirudin is a specific and reversible bivalent direct thrombin inhibitor. Bivalirudin specifically binds to both the catalytic site and to the anion-binding ...
Lepirudin is an anticoagulant that acts as a direct thrombin inhibitor. Lepirudin binds to both free and clot-bound thrombin. Lepirudin is approved for the trea...
Dabigatran etexilate(BIBR-1048) is the orally active prodrug of dabigatran; Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki va...
Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor.
AEBSF is a water soluble, irreversible serine protease inhibitor; inhibits proteases like chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.
Argatroban is an anticoagulant that is a direct thrombin inhibitor. Argatroban was approved in 2000 for prophylaxis or treatment of thrombosis in patients with ...
H-D-Phe-Pro-arginal is a thrombin inhibitor which is being developed by IVAX for the potential treatment of thromboembolic disorders. It has a similar efficacy ...
VE-1902 is a novel and selective inhibitor of thrombin. Study in vivo and in vitro showed that VE-1902 inhibits thrombin via binding to it reversibly.
Flovagatran is a thrombin inhibitor originated by Trigen Holdings AG. In Dec 2010, Phase-II for Thrombosis was discontinued.
Ximelagatran, an ester prodrug of melagatran, with anticoagulant effect, is the first member of direct thrombin inhibitors that can be taken orally.
GYKI14451 is a synthetic tripeptide inhibitor of thrombin. It has anti-atherosclerotic activity.
Odiparcil is a novel thrombin inhibitor as a beta-d-thioxyloside analog originated by Fournier Pharma. It is also a Glycosaminoglycan stimulant. Research for th...
GYKI-14451 is a synthetic tripeptide inhibitor of thrombin.It has anti-atherosclerotic activity.
Efegatran is a thrombin inhibitor under the development of Eli Lilly. It can be used for the treatment of thromboembolic disorders. No development reported was ...
Dabigatran is a very potent anticoagulant， shows that the terminal phenyl can be substituted by the more hydrophilic 2-pyridyl group without substantial loss of...